Scope
EAU neuro-urology guidance prioritises protection of the upper urinary tract alongside continence, bladder function and quality of life. Symptoms alone do not establish whether bladder pressures are safe. Assessment, treatment and lifelong surveillance should reflect the neurological condition, urodynamic risk, cognition, hand function, support and the person’s preferences.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Establish function and risk before treatment
- Take urinary, bowel, sexual and neurological histories, including pain, infection, haematuria and fever that warrant specific investigation. Assess quality of life with validated neurological-population tools and account for physical and cognitive disabilities when planning tests. [1]
- Document urogenital sensation and reflexes, anal sphincter and pelvic-floor function. Initial and routine assessment includes urinalysis, blood chemistry, bladder diary, residual urine, incontinence quantification and urinary-tract imaging; a diary preferably covers three consecutive days. [1]
- Recognise potentially life-threatening autonomic dysreflexia, usually with spinal injury at or above Th 6: systolic pressure rises more than 20 mmHg above baseline, sometimes with headache, flushing or sweating. Bladder/bowel distension and instrumentation can trigger it; monitor pressure and heart rate during invasive procedures in at-risk patients. [1]
- Perform noninvasive assessment before invasive urodynamics, then use same-session repeat measurements. Prefer video-urodynamics; if unavailable, combine filling cystometry with a pressure-flow study. Use physiological filling rates and body-warm saline. These are strong recommendations for neurological lower-tract dysfunction. [1]
- After spinal cord injury, obtain the first urodynamic study as soon as possible after critical care, within 3 months. Assess renal risk: in poor muscle mass, cystatin-C-based estimated filtration may detect chronic kidney disease more accurately than creatinine-based estimates. [1]
Reduce harmful pressures and support safe emptying
- Use shared decisions that consider culture, disability, cognition and caregiver support. For high storage pressure or poor compliance, prioritise a low-pressure reservoir and upper-tract protection, even when residual urine results; continence alone is not the treatment target. [1]
- Discourage Credé compression and Valsalva voiding unless urodynamics demonstrates safe intravesical pressures. Assisted emptying requires education and close surveillance. Do not use penile clamps with neurogenic detrusor overactivity or low compliance, because pressure injury and urinary-tract harm can result. [1]
- For neurogenic overactive-bladder symptoms, use an antimuscarinic or beta-3 agonist. Do not use beta-3 agonists intending to reduce urodynamically proven detrusor overactivity. Consider cognitive adverse effects of antimuscarinics and another treatment if cognition is affected. [1]
- Use an alpha blocker to reduce bladder-outlet resistance when indicated, but do not prescribe parasympathomimetics for underactive detrusor. If desmopressin is used for nocturnal polyuria, screen and monitor serum sodium; the source notes frequent hyponatraemia and uncertainty about optimal dosing. [1]
- When bladder emptying is inadequate, discuss intermittent versus indwelling catheterisation through shared decisions, including practical ability, risks and preferences. Thoroughly teach intermittent technique and optimise fluid intake, bowel care and catheterisation frequency; avoid indwelling routes where feasible because of complications. [1]
- Offer intravesical oxybutynin for neurogenic detrusor overactivity when oral treatment is poorly tolerated. If antimuscarinic therapy is ineffective, use detrusor botulinum toxin A; discuss UTI, retention and haematuria, including the possibility of needing intermittent catheterisation. [1]
- For low bladder compliance or refractory detrusor overactivity after less-invasive treatments fail, offer augmentation. Counsel about possible intermittent catheterisation and significant long-term morbidity, including metabolic problems, stones and perforation; lifelong follow-up remains essential. [1]
- Only treat neurogenic stress incontinence surgically when upper-tract risk and detrusor pressures are controlled. For women able to self-catheterise, an autologous sling is first-line; a synthetic sling is an alternative in selected women, with a weak recommendation. [1]
- For neurogenic stress incontinence with controlled upper-tract risk and detrusor pressures, offer an artificial urinary sphincter to men, discussing the elevated complication and reoperation burden. Selected women may receive one at an experienced centre, a weak recommendation. Consider sacral neuromodulation only in selected neurological patients. [1]
Distinguish symptomatic infection from bacteriuria
- A neurological patient’s UTI may present with new incontinence, spasticity, malaise, autonomic dysreflexia or fever rather than typical dysuria. Diagnose with clinical features plus urinalysis and culture; do not use dipstick screening alone and do not screen for or treat asymptomatic bacteriuria. [1]
- For symptomatic UTI in neurological lower-tract dysfunction, choose antibiotics from microbiology. When immediate treatment is necessary, such as fever, sepsis or extensive autonomic dysreflexia, use local and individual resistance patterns and previous cultures while awaiting results. [1]
- With recurrent UTIs, first optimise bladder storage and emptying and address stones or indwelling catheters that sustain infection. Avoid continuous long-term antibiotic prophylaxis and individualise prevention; no single optimal preventive measure is established for neurological lower-tract dysfunction. [1]
- The source recommends weekly cycling antibiotic prophylaxis only for selected spinal-cord-injury patients using intermittent catheterisation who have recurrent UTIs. Drinking-water bladder irrigation may be considered for catheter-associated UTI reduction, but that recommendation is weak; neither statement supplies a universal regimen. [1]
Address sexual health and lifelong surveillance
- Oral PDE5 inhibitors are first-line for neurogenic erectile dysfunction, but they are contraindicated with nitrates, including nitrates used for autonomic dysreflexia. Consider hypotension risk in high spinal lesions or multiple-system atrophy; intracavernosal therapy is an alternative when oral treatment is contraindicated or ineffective. [1]
- For sperm retrieval after spinal cord injury, use vibrostimulation or transrectal electroejaculation; after failure consider surgical retrieval and intracytoplasmic sperm injection. Counsel men with injury at or above Th 6 and fertility clinics about potentially life-threatening autonomic dysreflexia during sexual activity or ejaculation. [1]
- EAU advises against medical therapy for neurogenic sexual dysfunction in women. Manage fertility, pregnancy and delivery with a multidisciplinary, individualised approach reflecting the neurological condition and patient preferences; women with multiple sclerosis planning pregnancy should review current medication with their physician. [1]
- Individualise lifelong follow-up to risk and treatment. High-risk patients need regular upper-tract imaging and baseline plus repeated urodynamics; significant clinical change requires specialised reassessment. The discussion suggests approximately six-monthly upper-tract ultrasound in high-risk patients, not a fixed schedule for everyone. [1]
Limitations and use
- This selected summary does not reproduce every rehabilitation technique, surgical procedure, drug dose or fertility intervention. It is not a complete autonomic dysreflexia emergency treatment protocol. UTI drug choice and duration require severity, organism and resistance assessment; no universal antibiotic regimen is supplied. Follow-up intervals are risk-based and supported by limited high-level evidence, and the source does not establish a routine cystoscopy interval.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Neuro-urology
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.